Back


24/10/2017
U.S. FDA grants orphan drug designation to glepaglutide for the treatment of short bowel syndrome
The U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has granted an orphan drug designation to glepaglutide for the treatment of the rare disease short bowel syndrome (SBS)*. Glepaglutide is a Zealandinvented long-acting GLP-2 analog that may offer a [...]

Download the pdf file





X

X